Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Gill

Showing results (41-50 of 66) with videos related to

Pageof 7
Sort By:
Pediatric Blood & Cancer|June 2, 2018
A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicinMatteo Trucco, Julio C Barredo, John Goldberg, et al.
Nature Reviews. Disease Primers|December 8, 2022
OsteosarcomaHannah C Beird, Stefan S Bielack, Adrienne M Flanagan, et al.
Nature Reviews. Disease Primers|December 30, 2022
Author Correction: OsteosarcomaHannah C Beird, Stefan S Bielack, Adrienne M Flanagan, et al.
Disaster Medicine and Public Health Preparedness|February 6, 2026
Health Care Systems: Responsibilities and ResilienceCarol Iddins, Ziad Kazzi, Arthur Chang, et al.
Sarcoma|February 19, 2021
Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in OsteosarcomaYoav Zvi, Elif Ugur, Brian Batko, et al.
Pediatric Blood & Cancer|October 17, 2022
Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcomaDouglas Harrison, Jonathan Gill, Michael Roth, et al.
International Journal of Cancer|June 8, 2020
Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patientsIzhar S Batth, Long Dao, Arun Satelli, et al.
Scientific Reports|August 18, 2016
HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survivalPratistha Koirala, Michael E Roth, Jonathan Gill, et al.
Pediatric Blood & Cancer|July 25, 2020
Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortiumJonathan Gill, Wendong Zhang, Zhongting Zhang, et al.
Oncotarget|March 22, 2018
Detection of circulating tumor DNA in patients with osteosarcomaDavid M Barris, Shoshana B Weiner, Robert A Dubin, et al.
Pageof 7

Showing results (41-50 of 66) with videos related to

Sort By:
Pageof 7
Pediatric Blood & Cancer|June 2, 2018
A phase I window, dose escalating and safety trial of metformin in combination with induction chemotherapy in relapsed refractory acute lymphoblastic leukemia: Metformin with induction chemotherapy of vincristine, dexamethasone, PEG-asparaginase, and doxorubicinMatteo Trucco, Julio C Barredo, John Goldberg, et al.
Nature Reviews. Disease Primers|December 8, 2022
OsteosarcomaHannah C Beird, Stefan S Bielack, Adrienne M Flanagan, et al.
Nature Reviews. Disease Primers|December 30, 2022
Author Correction: OsteosarcomaHannah C Beird, Stefan S Bielack, Adrienne M Flanagan, et al.
Disaster Medicine and Public Health Preparedness|February 6, 2026
Health Care Systems: Responsibilities and ResilienceCarol Iddins, Ziad Kazzi, Arthur Chang, et al.
Sarcoma|February 19, 2021
Prognostic and Therapeutic Utility of Variably Expressed Cell Surface Receptors in OsteosarcomaYoav Zvi, Elif Ugur, Brian Batko, et al.
Pediatric Blood & Cancer|October 17, 2022
Evaluation of the pan-class I phosphoinositide 3-kinase (PI3K) inhibitor copanlisib in the Pediatric Preclinical Testing Consortium in vivo models of osteosarcomaDouglas Harrison, Jonathan Gill, Michael Roth, et al.
International Journal of Cancer|June 8, 2020
Cell surface vimentin-positive circulating tumor cell-based relapse prediction in a long-term longitudinal study of postremission neuroblastoma patientsIzhar S Batth, Long Dao, Arun Satelli, et al.
Scientific Reports|August 18, 2016
HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survivalPratistha Koirala, Michael E Roth, Jonathan Gill, et al.
Pediatric Blood & Cancer|July 25, 2020
Dose-response effect of eribulin in preclinical models of osteosarcoma by the pediatric preclinical testing consortiumJonathan Gill, Wendong Zhang, Zhongting Zhang, et al.
Oncotarget|March 22, 2018
Detection of circulating tumor DNA in patients with osteosarcomaDavid M Barris, Shoshana B Weiner, Robert A Dubin, et al.
Pageof 7